ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bemnifosbuvir

Also written as “AT-527”, “Bemnifosbuvir (BEM)” and “AT-527 + digoxin”.

Its studies are mostly in Hepatitis C, Chronic · COVID-19 · Renal Insufficiency, led by 2 companies.

Drug pageBemnifosbuvir: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 26, 202226 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Atea Pharmaceuticalsits history only240 open or runningphase 3since Nov 26, 2022Jul 13, 2017none ahead
Hoffmann-La Roche20 open or runningphase 3since May 10, 2021Jan 12, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 12, 2021First study: phase 2 study in COVID-19First studyNCT04709835 · 104 enrolled · Canada, Greece, Ireland and more
  2. May 10, 2021Phase 3 study in COVID-19NCT04889040 · 216 enrolled · Argentina, Belgium, Brazil and more
  3. Jul 28, 2021Named bemnifosbuvirINNProposed as its International Nonproprietary Name in WHO's List 125 · before, AT-527

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04889040COVID-19 · Argentina, Belgium, Brazil and more3TerminatedDec 2, 2021216
NCT04709835COVID-19 · Canada, Greece, Ireland and more2CompletedSep 17, 2021104

How it is read

Names in the registry

  • “AT-527”, 10 entries
  • “Bemnifosbuvir (BEM)”, 4 entries
  • “AT-527 + digoxin”, 2 entries
  • “AT-527 550 mg + midazolam”, 2 entries
  • “Buprenorphine/Naloxone + BEM/RZR”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.